Agenus Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Agenus is a clinical-stage immuno-oncology company developing antibody therapies, cell therapies through MiNK, and vaccine adjuvants through SaponiQx. The financial statements are unaudited. Dollar amounts below are in millions unless otherwise noted.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Total revenue | $22.9 | $25.9 |
| Operating loss | $54.3 | $35.5 |
| Net loss | $70.9 | $50.6 |
| Net loss attributable to Agenus common stockholders | $68.3 | $48.4 |
| Loss per common share, basic and diluted | $0.22 | $0.19 |
| Net cash used in operating activities | $58.5 | $52.4 |
- Revenue included $19.1 of non-cash royalty revenue associated with the previously sold GSK QS-21 royalty stream, $2.6 of research and development revenue, and $1.2 of service revenue. The filing does not provide a clear overall gross-margin figure.
- Research and development expense increased 35% to $57.1, primarily reflecting higher third-party program costs and increased personnel and subsidiary expenses. General and administrative expense decreased 4% to $18.2.
- Interest expense, net, was $16.6, mainly reflecting non-cash interest on the HCR royalty-sale liability.
- Cash, cash equivalents and short-term investments were $189.2 at quarter-end, down $4.1 from December 31, 2022. Cash and cash equivalents alone were $164.8. Operating cash use was partly offset by $60.6 of net proceeds from at-the-market (ATM) stock sales.
- Total liabilities were approximately $366.0; total debt principal was $14.0. The company also reported a net $269.4 liability related to the sale of future royalties and milestones, including $84.9 current. The 2015 subordinated notes were extended to February 2025.
- Total stockholders’ deficit was $53.1. Common shares issued rose from 305.6 million at year-end to 341.7 million at March 31, reflecting, among other issuances, approximately 33.8 million ATM shares sold during the quarter.
Changes versus Q1 2022
- Total revenue declined 12%; research and development revenue fell to $2.6 from $6.7, as the prior-year period included a $5.0 Gilead milestone.
- Non-cash royalty revenue increased to $19.1 from $17.6, attributed to higher GSK vaccine sales.
- Research and development expense rose 35%, while operating loss widened to $54.3 from $35.5 and net loss increased to $70.9 from $50.6.
- Operating cash use increased to $58.5 from $52.4. ATM net proceeds increased to $60.6 from $19.2.
Outlook, management commentary and risks
- Management stated that the $189.2 of cash, cash equivalents and short-term investments at March 31 was expected to fund liquidity needs for more than one year from issuance of the financial statements. Management may reduce spending, capital expenditures or operations and may seek collaborations, licensing arrangements, milestones, asset sales, project financing or further equity sales.
- The company expects significant losses and additional research and development spending. It said it cannot reliably estimate the cost or timing of completing development programs or when material cash inflows may begin. Product candidates require successful trials, regulatory approvals and market acceptance.
- Botensilimab, alone and with balstilimab, is a lead program; worldwide studies in colorectal cancer, melanoma and pancreatic cancer had been initiated. Management cited encouraging activity in “cold tumors,” including microsatellite-stable colorectal cancer, while clinical outcomes and development timing remain uncertain.
- Incyte notified Agenus of planned terminations of its OX40 program, effective October 2023, and GITR and an undisclosed program, effective May 2024; rights are expected to revert to Agenus upon termination. Incyte and Merck retain responsibility for development costs on their remaining partnered programs, subject to their agreements.
- HCR accounting is unusual: royalties from GSK are remitted to HCR, while Agenus records non-cash royalty revenue and related non-cash interest expense. The estimated effective annual interest rate on the HCR arrangement decreased to 26.7% during the quarter.
- After quarter-end, Agenus sold approximately 9.2 million ATM shares for $13.6 net proceeds through May 5, 2023. On May 1, it distributed 5.0 million MiNK shares to Agenus stockholders; Agenus retained approximately 62% ownership and voting control of MiNK.
- The filing reported no material changes to the risk factors in the 2022 Form 10-K and no material legal proceedings. Management concluded disclosure controls were effective; no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether clinical trial data and timelines for botensilimab, balstilimab and MiNK’s cell therapy support continued development and potential regulatory pathways.
- Whether the stated liquidity runway remains achievable given quarterly operating cash use, planned development spending, and the accessibility of subsidiary cash.
- Future ATM share sales, remaining sales capacity, and the resulting dilution to existing holders.
- GSK vaccine sales and the assumptions underlying the HCR liability, non-cash revenue recognition and interest expense.
- Partner decisions and milestones, including Incyte program terminations and the remaining Gilead, Merck and other collaboration opportunities.